Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
received:
17
03
2021
pubmed:
22
10
2021
medline:
3
6
2022
entrez:
21
10
2021
Statut:
epublish
Résumé
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer arising from lymphoblasts of T-cell origin. While TALL accounts for only 15% of childhood and 25% of adult ALL, 30% of patients relapse with a poor outcome. Targeted therapy of resistant and high-risk pediatric T-ALL is therefore urgently needed, together with precision medicine tools allowing the testing of efficacy in patient samples. Furthermore, leukemic cell heterogeneity requires drug response assessment at the single-cell level. Here we used single-cell mass cytometry to study signal transduction pathways such as JAK-STAT, PI3K-AKT-mTOR and MEK-ERK in 16 diagnostic and five relapsed T-ALL primary samples, and investigated the in vitro response of cells to Interleukin-7 (IL-7) and the inhibitor BEZ-235. T-ALL cells showed upregulated activity of the PI3K-AKT-mTOR and MEK-ERK pathways and increased expression of proliferation and translation markers. We found that perturbation induced by the ex vivo administration of either IL-7 or BEZ-235 reveals a high degree of exclusivity with respect to the phospho-protein responsiveness to these agents. Notably, these response signatures were maintained from diagnosis to relapse in individual patients. In conclusion, we demonstrated the power of mass cytometry single-cell profiling of signal transduction pathways in T-ALL. Taking advantage of this advanced approach, we were able to identify distinct clusters with different responsiveness to IL-7 and BEZ-235 that can persist at relapse. Collectively our observations can contribute to a better understanding of the complex signaling network governing T-ALL behavior and its correlation with influence on the response to therapy.
Identifiants
pubmed: 34670357
doi: 10.3324/haematol.2021.278796
pmc: PMC9152963
doi:
Substances chimiques
Interleukin-7
0
MTOR protein, human
EC 2.7.1.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1293-1310Références
Blood. 1991 Aug 1;78(3):564-70
pubmed: 1650261
J Exp Med. 2014 Apr 7;211(4):701-13
pubmed: 24687960
Leukemia. 2020 Jul;34(7):1730-1740
pubmed: 31992840
Clin Cancer Res. 2016 Feb 1;22(3):621-32
pubmed: 26080839
Biotechniques. 2003 Feb;34(2):374-8
pubmed: 12613259
Front Oncol. 2015 Feb 16;5:24
pubmed: 25763354
Adv Biol Regul. 2014 Sep;56:6-21
pubmed: 24819383
Nat Commun. 2015 Jan 07;6:5794
pubmed: 25565005
Cancer Drug Resist. 2019 Sep 19;2(3):647-664
pubmed: 35582582
Blood. 2014 Jul 24;124(4):567-78
pubmed: 24904117
Int J Mol Sci. 2019 Jun 20;20(12):
pubmed: 31226848
Cell Signal. 2017 Oct;38:10-25
pubmed: 28645565
Blood. 2011 Jun 16;117(24):6650-9
pubmed: 21527520
Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):7858-7866
pubmed: 30536331
Cytometry B Clin Cytom. 2018 Jan;94(1):82-93
pubmed: 28187514
Blood. 1995 Nov 15;86(10):3861-8
pubmed: 7579354
Nat Rev Cancer. 2008 Dec;8(12):976-90
pubmed: 19029958
Cytometry A. 2016 Mar;89(3):292-300
pubmed: 26355391
Nat Biotechnol. 2012 Sep;30(9):858-67
pubmed: 22902532
Cancer Cell. 2013 Dec 9;24(6):766-76
pubmed: 24291004
Haematologica. 2012 Sep;97(9):1405-13
pubmed: 22491738
J Clin Oncol. 2009 Nov 1;27(31):5168-74
pubmed: 19805690
Oncotarget. 2016 Sep 27;7(39):64071-64088
pubmed: 27590521
J Exp Med. 1993 Feb 1;177(2):305-16
pubmed: 7678850
J Pediatr Hematol Oncol. 2014 Aug;36(6):413-8
pubmed: 24942023
Blood. 2017 Mar 2;129(9):1113-1123
pubmed: 28115373
J Clin Invest. 2020 Feb 3;130(2):863-876
pubmed: 31687977
Nat Genet. 2017 Aug;49(8):1211-1218
pubmed: 28671688
Leukemia. 2016 Sep;30(9):1832-43
pubmed: 27174491
Semin Hematol. 2009 Jan;46(1):1-2
pubmed: 19100362
Blood. 2011 Aug 25;118(8):2077-84
pubmed: 21719599
Lancet Oncol. 2009 Feb;10(2):147-56
pubmed: 19147408
Nat Genet. 2011 Sep 04;43(10):932-9
pubmed: 21892159
Haematologica. 2015 Oct;100(10):1301-10
pubmed: 26206799
Cancer Cell. 2002 Feb;1(1):75-87
pubmed: 12086890
Science. 2011 May 6;332(6030):687-96
pubmed: 21551058
Blood. 2005 Jul 1;106(1):274-86
pubmed: 15774621
Sci Rep. 2019 Jun 20;9(1):8914
pubmed: 31222035
Cancer Res. 2011 Jul 15;71(14):4780-9
pubmed: 21593192
Nat Rev Immunol. 2003 Apr;3(4):317-30
pubmed: 12669022
Blood. 2017 Dec 21;130(25):2750-2761
pubmed: 29101238
Haematologica. 2012 Jul;97(7):1048-56
pubmed: 22271901
Oncotarget. 2014 May 30;5(10):3168-72
pubmed: 24930440
Semin Cancer Biol. 2006 Aug;16(4):253-64
pubmed: 16904903
Cancer Cell. 2016 Dec 12;30(6):849-862
pubmed: 27916615
J Immunol. 2015 Feb 15;194(4):2022-31
pubmed: 25609839
Blood Rev. 2019 Nov;38:100591
pubmed: 31353059
Cytometry A. 2014 Jan;85(1):78-87
pubmed: 24038859
Blood Adv. 2018 Sep 11;2(17):2199-2213
pubmed: 30185437
Oncogene. 2005 Aug 4;24(33):5252-7
pubmed: 15870688
PLoS Med. 2016 Dec 20;13(12):e1002200
pubmed: 27997540
Nat Commun. 2018 May 21;9(1):2002
pubmed: 29784946
Nat Med. 2007 Oct;13(10):1203-10
pubmed: 17873882
Blood. 2008 Aug 1;112(3):733-40
pubmed: 18411416
Leukemia. 2017 Dec;31(12):2568-2576
pubmed: 28484265
Cancer Cell. 2011 Apr 12;19(4):484-97
pubmed: 21481790
Cytometry B Clin Cytom. 2020 Nov;98(6):491-503
pubmed: 32479694
J Clin Invest. 2008 Nov;118(11):3762-74
pubmed: 18830414
J Exp Med. 2011 May 9;208(5):901-8
pubmed: 21536738
Cytometry A. 2019 Aug;95(8):910-916
pubmed: 31058420
Nature. 2012 Jan 11;481(7380):157-63
pubmed: 22237106
Cell Syst. 2018 May 23;6(5):612-620.e5
pubmed: 29605184